Author(s): Navakanth Raju Ramayanam, Rajesh Nanda Amarnath, Thangavel Mahalingam Vijayakumar

Email(s): vijaypractice@yahoo.com

DOI: 10.52711/0974-360X.2022.00720   

Address: Navakanth Raju Ramayanam, Rajesh Nanda Amarnath, Thangavel Mahalingam Vijayakumar*
Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu, India.
*Corresponding Author

Published In:   Volume - 15,      Issue - 9,     Year - 2022


ABSTRACT:
Pharmacogenomics is the study of an individual's response to drugs as a result of their genetic makeup. Pharmacogenomics has been merged with pharmacology and genomics to produce safe and effective drugs that are customized to the unique genetic profile of each individual. Drug prescribing focused on pharmacogenomics opens up a modern avenue for developing and prescribing safe and efficient drugs to specific patients. Patients that are prescribed medications that are more appropriate to them based on their physiology and lifestyle characteristics are referred to as obtaining personalized medicine. The medicinal use of molecularly targeted agents, which are commonly used for customized therapies, could aid in disease detection in a small number of patients. To assess the advantage of selected patients with genomic changes to a given treatment, clinical trial research designs for different diagnostics and therapeutics must aim for rate-limiting steps. Precision medicine techniques are used to classify specific patients' genetic flaws in the hopes of identifying new disease-prevention treatments. Precision medicine, on the other hand, is more precise in clinical practice, with an emphasis on identifying new therapeutic targets, recent advances in molecular testing trials, and a variety of advanced approaches are available for collecting biological samples in clinical practice to conduct genomic processing. Pharmacogenomics biomarkers use customized drugs to anticipate the incidence of diseases in the future. Individual precision medicine can overcome the limitations of traditional medicine in terms of disease prevention.


Cite this article:
Navakanth Raju Ramayanam, Rajesh Nanda Amarnath, Thangavel Mahalingam Vijayakumar. Pharmacogenetic Biomarkers and Personalized Medicine: Upcoming Concept in Pharmacotherapy. Research Journal of Pharmacy and Technology. 2022; 15(9):4289-2. doi: 10.52711/0974-360X.2022.00720

Cite(Electronic):
Navakanth Raju Ramayanam, Rajesh Nanda Amarnath, Thangavel Mahalingam Vijayakumar. Pharmacogenetic Biomarkers and Personalized Medicine: Upcoming Concept in Pharmacotherapy. Research Journal of Pharmacy and Technology. 2022; 15(9):4289-2. doi: 10.52711/0974-360X.2022.00720   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-9-80


REFERENCES:
1.    Scott SA. Personalizing medicine with clinical pharmacogenetics. Genetics in Medicine. 2011 Dec; 13(12):987-95. doi: 10.1097/GIM.0b013e318238b38c
2.    Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland‐van der Zee AH, Mulder H, Rongen GA, Van Schaik RH, Schalekamp T, Touw DJ, van der Weide J. Pharmacogenetics: from bench to byte—an update of guidelines. Clinical Pharmacology & Therapeutics. 2011 May; 89(5):662-73. DOI: 10.1038/clpt.2011.34
3.    Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clinical Pharmacology & Therapeutics. 2012 Oct; 92(4):467-75. doi: 10.1038/clpt.2012.120
4.    Ni X, Zhang W, Huang RS. Pharmacogenomics discovery and implementation in genome‐wide association studies era. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2013 Jan; 5(1):1-9. DOI: 10.1002/wsbm.1199
5.    Raza S, Hall A. Genomic medicine and data sharing. British medical bulletin. 2017 Sep 1:1-1. DOI: 10.1093/bmb/ldx024
6.    Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. The pharmacogenomics journal. 2013 Feb; 13(1):1-1. DOI: 10.1038/tpj.2012.45
7.    Weinstein JN. Pharmacogenomics—teaching old drugs new tricks. DOI: 10.1056/NEJM200011093431910
8.    Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, The Journal of the American Society of Hematology. 2000 Sep 1; 96(5):1816-9. https://doi.org/10.1182/blood.V96.5.1816
9.    Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends in Molecular Medicine. 2001 May 1; 7(5):201-4.DOI: 10.1016/s1471-4914(01)01986-4
10.    Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. New England Journal of Medicine. 2003 Feb 6; 348(6):538-49. DOI: 10.1056/NEJMra020526
11.    Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001 Feb 15; 409(6822):928-34. DOI: 10.1038/35057149
12.    Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annual review of Pharmacology and Toxicology. 1997 Apr; 37(1):269-96.DOI: 10.1146/annurev.pharmtox.37.1.269
13.    Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?. American Journal of Human Genetics. 1997 Feb; 60(2):265.
14.    Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 Oct 15; 286(5439):487-91.DOI: 10.1126/science.286.5439.487
15.    Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001 Feb 15; 409(6822):928-34.DOI: 10.1038/35057149
16.    Stoneking M. Single nucleotide polymorphisms. From the evolutionary past. Nature. 2001 Feb 15; 409(6822):821-2. DOI: 10.1038/35057279
17.    Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman‐Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. British Journal of Clinical Pharmacology. 2001 Oct; 52(4):447-50. DOI: 10.1046/j.0306-5251.2001.01460.x
18.    Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD. The sequence of the human genome. Science. 2001 Feb 16; 291(5507):1304-51. DOI: 10.1126/science.1058040
19.    Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, Ingelman-Sundberg M, Papaluca-Amati M. Pharmacogenomic information in drug labels: European Medicines Agency perspective. The Pharmacogenomics Journal. 2015 Jun; 15(3):201-10. DOI: 10.1038/tpj.2014.86
20.    Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J. Initial sequencing and analysis of the human genome. Nature [Internet]. DOI: 10.1038/35057062
21.    Padh H. Human genome project and pharmacogenomics: Leading towards individualized medication. Indian Drugs-Bombay-. 2001; 38(4):160-3.
22.    Schork NJ. Genetic parts to a preventive medicine whole. Genome Medicine. 2013 Jun; 5(6):1-4. DOI: 10.1186/gm458
23.    Patel CJ, Sivadas A, Tabassum R, Preeprem T, Zhao J, Arafat D, Chen R, Morgan AA, Martin GS, Brigham KL, Butte AJ. Whole genome sequencing in support of wellness and health maintenance. Genome Medicine. 2013 Jun; 5(6):1-4. DOI: 10.1186/gm462
24.    Luzzatto L, Seneca E. G6 PD deficiency: a classic example of pharmacogenetics with on‐going clinical implications. British Journal of Haematology. 2014 Feb; 164(4):469-80. DOI: 10.1111/bjh.12665
25.    Schork NJ. Personalized medicine: time for one-person trials. Nature News. 2015 Apr 30; 520(7549):609. DOI: 10.1038/520609a
26.    Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nature reviews Drug Discovery. 2013 May; 12(5):358-69. DOI: 10.1038/nrd3979
27.    Schork NJ, Nazor K. Integrated genomic medicine: A paradigm for rare diseases and beyond. Advances in Genetics. 2017 Jan 1; 97:81-113. DOI: 10.1016/bs.adgen.2017.06.001
28.    Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015 Jun 2; 313(21):2119-20. DOI: 10.1001/jama.2015.3595
29.    Kaphingst KA, McBride CM, Wade C, Alford SH, Reid R, Larson E, Baxevanis AD, Brody LC. Patients’ understanding of and responses to multiplex genetic susceptibility test results. Genetics in Medicine. 2012 Jul; 14(7):681-7. DOI: 10.1038/gim.2012.22
30.    Haga SB, Moaddeb J, Mills R, Voora D. Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. Pharmacogenomics. 2017 Mar; 18(4):327-35. DOI: 10.2217/pgs-2016-0175

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available